Tco conjugates and methods for delivery of therapeutic agents
US-2017095580-A1 · Apr 6, 2017 · US
TCO conjugates and methods for delivery of therapeutic agents
US10342882B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10342882-B2 |
| Application number | US-201615265158-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 14, 2016 |
| Priority date | Mar 14, 2014 |
| Publication date | Jul 9, 2019 |
| Grant date | Jul 9, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides a method for selective delivery of a therapeutic or diagnostic agent to a targeted organ or tissue by implanting a biocompatible solid support in the patient being linked to a first binding agent, and administering a second binding agent to the patient linked to the therapeutic or diagnostic agent, such that the therapeutic or diagnostic agent accumulates at the targeted organ or tissue.
First claim
Opening claim text (preview).
What is claimed is: 1. A bioactive composition comprising: a therapeutic agent other than doxorubicin, vancomycin, and paclitaxel; a binding agent comprising a trans-cyclooctene; and a linker comprising from about 1 to about 10 linking atoms, covalently linking the binding agent to the therapeutic agent. 2. The composition of claim 1 , wherein the linker comprises the structure of: 3. The composition of claim 1 , wherein the binding agent and the linker together have the structure selected from the group consisting of 4. The bioactive composition of claim 1 , wherein the therapeutic agent is daptomycin, irinotecan, SN-38, amoxicillin, cyclic AMP, doxycyclin, amphotericin, ixabepilone, podophyllotoxin, patupilone, or rapamycin. 5. The bioactive composition of claim 4 , wherein the therapeutic agent is daptomycin. 6. The bioactive composition of claim 4 , wherein the therapeutic agent is irinotecan. 7. The bioactive composition of claim 4 , wherein the therapeutic agent is SN-38. 8. The bioactive composition of claim 4 , wherein the therapeutic agent is amoxicillin. 9. The bioactive composition of claim 4 , wherein the therapeutic agent is cyclic AMP. 10. The bioactive composition of claim 4 , wherein the therapeutic agent is doxycyclin. 11. The bioactive composition of claim 4 , wherein the therapeutic agent is amphotericin. 12. A bioactive composition comprising a therapeutic agent other than doxorubicin, wherein the therapeutic agent is linked by a covalent bond to a structure 13. The bioactive composition of claim 12 , wherein the therapeutic agent is vancomycin, paclitaxel, daptomycin, etoposide, irinotecan, SN-38, amoxicillin, cyclic AMP, doxycyclin, amphotericin, ixabepilone, podophyllotoxin, patupilone, or rapamycin. 14. The bioactive composition of claim 13 , wherein the therapeutic agent is vancomycin. 15. The bioactive composition of claim 13 , wherein the therapeutic agent is paclitaxel. 16. The bioactive composition of claim 13 , wherein the therapeutic agent is daptomycin. 17. The bioactive composition of claim 13 , wherein the therapeutic agent is SN-38. 18. A bioactive composition comprising: a diagnostic agent; a binding agent comprising a trans-cyclooctene; and a linker comprising from about 1 to about 10 linking atoms, covalently linking the binding agent to the diagnostic agent. 19. The bioactive composition of claim 18 , wherein the diagnostic agent is an optical probe.
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
Antibacterial agents · CPC title
the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems · CPC title
chelates from cyclic ligands, e.g. DOTA · CPC title
with carbocyclic rings directly attached to the carboxamido radical · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10342882B2 cover?
- The present invention provides a method for selective delivery of a therapeutic or diagnostic agent to a targeted organ or tissue by implanting a biocompatible solid support in the patient being linked to a first binding agent, and administering a second binding agent to the patient linked to the therapeutic or diagnostic agent, such that the therapeutic or diagnostic agent accumulates at the t…
- Who is the assignee on this patent?
- Univ California, Univ New York State Res Found
- What technology area does this patent fall under?
- Primary CPC classification A61K38/14. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jul 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 6 related publications on this page (citations in our corpus or others sharing the same primary CPC).